{"id":1299,"date":"2003-08-01T12:01:00","date_gmt":"2003-08-01T10:01:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2003\/benoetigen-patienten-mit-fortgeschrittenem-m-hodgkin-eine-adjuvante-bestrahlung-nach-der-polychemotherapie"},"modified":"2022-03-17T14:10:29","modified_gmt":"2022-03-17T13:10:29","slug":"benoetigen-patienten-mit-fortgeschrittenem-m-hodgkin-eine-adjuvante-bestrahlung-nach-der-polychemotherapie","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2003\/benoetigen-patienten-mit-fortgeschrittenem-m-hodgkin-eine-adjuvante-bestrahlung-nach-der-polychemotherapie","title":{"rendered":"Ben\u00f6tigen Patienten mit fortgeschrittenem M. Hodgkin eine adjuvante Bestrahlung nach der Polychemotherapie?"},"content":{"rendered":"<p>Dieser wichtigen Frage widmete sich eine Studie der European Organization for Research and Treatment of Cancer Lymphoma Group (Aleman, B.M.P., et al.: N. Engl. J. Med. 2003, 348, 2396). Der Nutzen einer adjuvanten lokalen Bestrahlung der bei Erstdiagnose betroffenen nodalen oder extranodalen Manifestationen nach Erreichen einer kompletten Remission (CR) durch Polychemotherapie wird auf Grund der [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Dieser wichtigen Frage widmete sich eine Studie der European Organization for Research and Treatment of Cancer Lymphoma Group (Aleman, B.M.P., et al.: N. Engl. J. Med. 2003, 348, 2396). Der Nutzen einer adjuvanten lokalen Bestrahlung der bei Erstdiagnose betroffenen nodalen oder extranodalen Manifestationen nach Erreichen einer kompletten Remission (CR) durch Polychemotherapie wird auf Grund der [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[2887,271,2313,2312,1410,262,264],"class_list":["post-1299","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-bestrahlung","tag-chemotherapie","tag-lymphogranulomatose","tag-m-hodgkin","tag-polychemotherapie","tag-zytostatika","tag-zytostatische-therapie"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/1299","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=1299"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/1299\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=1299"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=1299"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=1299"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}